WEKO3
-
RootNode
アイテム
Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients
http://hdl.handle.net/10091/00021019
http://hdl.handle.net/10091/00021019d03e00a7-b049-41b9-8cbe-634368b0e396
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
26461687_06.pdf (3.0 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2018-11-05 | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients | |||||||||||||
| 言語 | ||||||||||||||
| 言語 | eng | |||||||||||||
| DOI | ||||||||||||||
| 関連識別子 | https://doi.org/10.2340/00015555-2748 | |||||||||||||
| 関連名称 | 10.2340/00015555-2748 | |||||||||||||
| キーワード | ||||||||||||||
| 主題 | melanoma, circulating tumour DNA, anti-programmed cell death-1 antibody, BRAF, NRAS, droplet digital PCR | |||||||||||||
| 資源タイプ | ||||||||||||||
| 資源 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||
| タイプ | journal article | |||||||||||||
| 著者 |
Ashida, Atsuko
× Ashida, Atsuko
× Sakaizawa, Kaori
× Uhara, Hisashi
× Okuyama, Ryuhei
|
|||||||||||||
| 信州大学研究者総覧へのリンク | ||||||||||||||
| 氏名 | Ashida, Atsuko | |||||||||||||
| URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.PCcebUym.html | |||||||||||||
| 出版者 | ||||||||||||||
| 出版者 | ACTA DERMATO-VENEREOLOGICA | |||||||||||||
| 引用 | ||||||||||||||
| 内容記述 | ACTA DERMATO-VENEREOLOGICA. 97:1212-1218(2018) | |||||||||||||
| 書誌情報 |
ACTA DERMATO-VENEREOLOGICA 巻 97, 号 10, p. 1212-1218, 発行日 2017-11 |
|||||||||||||
| 抄録 | ||||||||||||||
| 内容記述 | Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAFmutant or NRASmutant) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2?4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy. | |||||||||||||
| 資源タイプ（コンテンツの種類） | ||||||||||||||
| ISSN | ||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||
| 収録物識別子 | 0001-5555 | |||||||||||||
| PubMed | ||||||||||||||
| 識別子タイプ | PMID | |||||||||||||
| 関連識別子 | https://www.ncbi.nlm.nih.gov/pubmed/28681063 | |||||||||||||
| 関連名称 | 28681063 | |||||||||||||
| 権利 | ||||||||||||||
| 権利情報 | Journal Compilation © 2017 Acta Dermato-Venereologica. This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta | |||||||||||||
| 出版タイプ | ||||||||||||||
| 出版タイプ | VoR | |||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||
| WoS | ||||||||||||||
| URL | http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000419735400010 | |||||||||||||
